Scoop: Saman­tha Truex de­parts At­las to head $200M Or­biMed-backed im­munol­o­gy start­up

Af­ter long­time biotech ex­ec­u­tive Sam Truex an­nounced last year she was shut­ting down her short-lived im­munol­o­gy start­up Quench Bio, she said she planned to stay at At­las Ven­ture to help build a new start­up with many of her erst­while Quench em­ploy­ees.

A lit­tle less than a year lat­er, though, Truex ap­pears to have de­part­ed to lead a well-backed start­up from a ri­val firm, Or­biMed.

Two weeks ago, Truex post­ed a job list­ing on LinkedIn for head of trans­la­tion­al re­search at Up­stream Bio. Up­stream, the post said, had al­ready raised a $200 mil­lion round led by Or­biMed to de­vel­op drugs for in­flam­ma­to­ry dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER